Skip to main content

Table 4 Adverse Events

From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade Not Determined
  No. Patients (%) N = 125
Hematologic      
Anemia 31 (25) 12 (10) 1 (<1) 0 6 (5)
Leukopenia 24 (19) 8 (6) 3 (2) 1 (<1) 6 (5)
Neutropenia 12 (10) 0 0 0 19 (15)
Thrombocytopenia 14 (11) 4 (3) 1 (<1) 1(<1) 6 (5)
Non-hematologic      
Skin/hand-foot syndrome 20 (16) 17 (14) 7 (6) 1 (<1) 2 (2)
Pain 22 (18) 8 (6) 4 (3) 0 4 (3)
Alopecia 13 (10) 6 (5) - - 7 (6)
Nausea 25 (20) 4 (3) 0 0 3 (2)
Stomatitis 16 (13) 6 (5) 2 (2) 0 5 (4)
Vomiting 5 (4) 2 (2) 1 (<1) 0 4 (3)
Diarrhea 3 (2) 3 (2) 0 0 5 (4)
Infection 0 1 (<1) 0 0 0
Fatigue 0 0 1 (<1) 0 0